Journal
JOURNAL OF POLYMER SCIENCE
Volume 58, Issue 14, Pages 2010-2021Publisher
WILEY
DOI: 10.1002/pol.20200303
Keywords
backbone degradable polymers; controlled polymerization; polymer-drug conjugates; precision polymers; RAFT polymerization; targeted drug delivery
Categories
Funding
- Engineering and Physical Sciences Research Council [EP/M014649/]
- EPSRC [EP/M014649/1] Funding Source: UKRI
Ask authors/readers for more resources
Despite the recent advances of controlled polymerization methods over the last decades, the lack of backbone degradability of well-defined polymers remains a major synthetic challenge that limits the full exploitation of polymer-drug conjugates (PDCs) in clinical practice. Here, we report the copolymerization of a cyclic ketene acetal (CKA) and a vinyl-based drug-monomer as a proof-of-concept approach to prepare model polyester-based prodrugs via reversible addition-fragmentation chain-transfer (RAFT) polymerization. We demonstrate the versatility of the system toward backbone degradability and control over the chain length while maintaining both low dispersity (D-M) and homogenous distribution of degradation points along the main polymer chain. The resulting PDCs exhibit unique self-assembly properties and potent cytotoxicity against pancreatic cancer cells. A methacrylate prodrug is copolymerized with a CKA co-monomer using RAFT polymerization producing a backbone degradable PDC with well-defined molecular structure. The resulting PDC undergoes controlled backbone degradation and produces by-products of narrow dispersity and low toxicity. In addition, it is demonstrated that the insertion of degradation segments does not affect the cytotoxic properties of the PDC under in vitro conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available